Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

New class of
regulated cell and
gene therapies

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Bispecific antibodies
to improve the treatment
of serious diseases

First-in-class
RNA therapies
for severe genetic diseases

Breakthrough computer-aided
drug design
for transformative medicines

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Next generation
synthetic biology platform
for novel therapeutics

Universal
cell-based
cancer immunotherapy

Therapies for rare,
debilitating, and underserved
neurological diseases

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

Novel therapeutics
targeting
diseases of aging

Novel therapies
for severe, highly drug-resistant
bacterial infections

Mouse platforms
for the generation of
fully human antibodies

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Discovering new medicines
for severe
neurodegenerative diseases

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Cell and gene therapies
for rare diseases
and cancer

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Cancer therapeutics
targeting anabolic
tumor metabolism

Innovative
micro-RNA-based
therapies

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Minimally invasive
heart valve
devices

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

Next-generation oncolytic
immunotherapies for
cancer treatment

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases

Biomarker-guided therapies
for chronic pain
and inflammation

Novel biologic
therapeutics for
autoimmune diseases

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Small molecule
drug design
using statistical modeling

Proprietary pharmaceuticals
for neonatal care
and pediatrics